ClinicalTrials.Veeva

Menu

Optimal Effect-site Concentration of Remifentanil for Inhibiting Response to Laryngeal Mask Airway (LMA) Removal

S

Sangjin Park

Status

Completed

Conditions

Respiratory Complication

Treatments

Drug: Remifentanil

Study type

Interventional

Funder types

Other

Identifiers

Details and patient eligibility

About

This study was designed to determine the optimal dose of remifentanil that can prevent the complications associated with the removal of LMA without delaying emergence.

Full description

Patients were randomly assigned to one of four groups. All patients received a predetermined effect-site concentrations (Ce) of remifentanil by target-controlled infusion (TCI) according to their group assignments (R0, remifentanil Ce of 0 ng/ml; R0.5, remifentanil Ce of 0.5 ng/ml; R1.0, remifentanil Ce of 1.0 ng/ml; R1.5, remifentanil Ce of 1.5 ng/ml) from 10 minutes before the end of surgery to LMA removal. Airway complications (airway obstruction, desaturation, breath holding, and coughing), nausea, and vomiting were assessed during the emergence phase.

Enrollment

128 patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • American Society of Anesthesiologists physical status 1 or 2
  • undergoing lower extremity surgery under general anesthesia

Exclusion criteria

  • suspected difficult airways
  • respiratory disease (chronic obstructive pulmonary disease, upper respiratory infection)
  • body mass index > 30 kg/m2
  • allergies to the study drugs
  • a history of gastric reflux

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

128 participants in 4 patient groups

group R0
No Intervention group
Description:
remifentanil Ce of 0 ng/ml
group R0.5
Active Comparator group
Description:
remifentanil Ce of 0.5 ng/ml
Treatment:
Drug: Remifentanil
group R1.0
Active Comparator group
Description:
remifentanil Ce of 1.0 ng/ml
Treatment:
Drug: Remifentanil
group R1.5
Active Comparator group
Description:
remifentanil Ce of 1.5 ng/ml
Treatment:
Drug: Remifentanil

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems